Sanofi Unruffled By JAK Threat To Dupixent
As Blockbuster Hits €5.25bn In 2021 Sales
CEO Paul Hudson tells Scrip that in an atopic dermatitis market that has a standard of care like Dupixent, "it's hard to justify the role of a JAK unless somebody has, frankly, failed everything else."
